Marinus Pharmaceuticals traded at $4.79 this Wednesday November 30th, decreasing $0.01 or 0.21 percent since the previous trading session. Looking back, over the last four weeks, Marinus Pharmaceuticals lost 16.70 percent. Over the last 12 months, its price fell by 54.60 percent. Looking ahead, we forecast Marinus Pharmaceuticals to be priced at 4.42 by the end of this quarter and at 4.00 in one year, according to Trading Economics global macro models projections and analysts expectations.


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Peers Price Day Year
Eisai 9,767.00 435.00 4.66% 44.06%
Acadia Pharmaceuticals 15.58 0.91 6.20% -17.57%
ALKERMES 24.78 0.76 3.16% 15.42%
Amgen 286.40 4.41 1.56% 42.63%
Aptinyx Inc 0.28 -0.01 -1.79% -86.97%
Biogen 305.17 13.76 4.72% 32.97%
Enanta Pharmaceuticals 43.79 1.83 4.36% -48.02%
Esperion Therapeutics 6.70 0.16 2.45% -16.67%
Gilead Sciences 87.83 2.07 2.41% 27.42%
Intercept Pharmaceuticals 14.91 0.67 4.71% -5.99%
Incyte Corp 79.67 1.87 2.40% 22.64%
Intra Cellular Therapies 54.22 1.37 2.59% 40.69%
Marinus Pharmaceuticals 4.79 -0.01 -0.21% -54.60%
Neurocrine Biosciences 127.06 5.32 4.37% 57.27%
Minerva Neurosciences 3.54 0.20 5.99% 291.25%
PTC Therapeutics 41.49 1.14 2.83% 15.47%
Regeneron Pharmaceuticals 751.62 15.62 2.12% 19.19%
Sarepta Therapeutics 122.81 5.71 4.88% 49.42%
Supernus Pharmaceuticals 36.72 0.72 2.00% 19.03%
UCB 76.78 -0.36 -0.47% -20.55%
Vertex Pharmaceuticals 316.40 0.07 0.02% 54.76%

Indexes Price Day Year
USND 11468 484.22 4.41% -24.82%

Marinus Pharmaceuticals
Marinus Pharmaceuticals Inc is a United States-based biopharmaceutical company. The Company offers development and commercialization of medical drugs for the treatment of serious neurological and psychiatric disorders such as epilepsy, post-traumatic stress, and fragile-x syndrome. Its clinical-stage product candidate, ganaxolone, is a modulator being developed in various dose forms, including intravenous, oral capsule and oral liquid, intended to provide more treatment options to adult and pediatric patient populations in both acute and chronic care settings.